Tissue factor activity on microvesicles from cancer patients.
Fanny EnderAnnika FreundTabea QueckeCorinna SteidelPiet ZamzowNikolas von BubnoffFrank GieselerPublished in: Journal of cancer research and clinical oncology (2019)
We suggest that MVs instead of whole EV preparations, and TF activity rather than its antigenic quantification should be used in clinical studies for identifying patients with progressive tumors at high risk for VTE.
Keyphrases